Stephen Wayne Hughes

US Patent:

6492166, Dec 10, 2002

Filed:

Jan 19, 2001

Appl. No.:

09/744022

Inventors:

Andrea L. Ferris - Frederick MD
Stephen H. Hughes - Smithsburg MD

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

C12N 1574

US Classification:

4353201, 435455, 435456, 536 231

Abstract:

An Avian-derived retroviral vector from which the Constitutive Transport Element (CTE) has been removed and replaced with a genetic fragment from a mammalian virus in order to produce a vector that is replication competent in at least one non-native cell type without the need for a âhelperâ virus, and that is unlikely to recombine with endogenous mammalian viruses, making it both safe and simple to use in research and gene-therapy applications.

US Patent:

6794188, Sep 21, 2004

Filed:

Sep 24, 2001

Appl. No.:

09/961933

Inventors:

Eugene Barsov - Frederick MD
Stephen H. Hughes - Smithsburg MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 1586

US Classification:

435456, 435325, 4353201, 435455, 514 44, 424 931, 424 932, 800 13, 800 18

Abstract:

Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.

US Patent:

8513214, Aug 20, 2013

Filed:

Nov 10, 2008

Appl. No.:

12/741873

Inventors:

Maqbool A. Siddiqui - Silver Spring MD, US
Victor E. Marquez - Montgomery Village MD, US
Stephen H. Hughes - Smithsburg MD, US
Paul L. Boyer - Greencastle PA, US

Assignee:

The United States of America as Represented by the Secretary of the Dept. of Health and Human Services - Washington DC

International Classification:

A01N 43/04
A61K 31/70
C07H 19/16
C07H 19/167
C07H 19/173
C12Q 1/70

US Classification:

514 45, 514 46, 435 5, 536 2721, 536 276

Abstract:

The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4′-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay.

US Patent:

60965347, Aug 1, 2000

Filed:

Nov 28, 1997

Appl. No.:

8/875509

Inventors:

Eugene Barsov - Frederick MD
Stephen H. Hughes - Smithsburg MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC

International Classification:

C12N 1500
C12N 700
C12N 510

US Classification:

4353201

Abstract:

Recombinant avian sarcoma leukosis virus (ASLV)-derived retrovirus vectors having an expanded host range are described. The host range is expanded by the replacement of the ASLV envelope gene by an envelope gene from a virus capable of infecting both mammalian and avian cells. The resulting recombinant ASLV-derived retroviral vectors can replicate efficiently in avian cells, infect both avian and mammalian cells in high titer, and are replication-defective in mammalian cells. Thus, they are quite safe and advantageous for use in gene therapy and vaccines.

US Patent:

20170305904, Oct 26, 2017

Filed:

May 8, 2017

Appl. No.:

15/589590

Inventors:

- Bethesda MD, US
Steven Smith - Thurmont MD, US
Mathieu Metifiot - Saint Andre de Cubzac, FR
Barry Johnson - Chincoteague VA, US
Christophe Marchand - Silver Spring MD, US
Stephen H. Hughes - Smithsburg MD, US
Yves Pommier - Bethesda MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Serv - Bethesda MD

International Classification:

C07D 471/04
C07D 215/60
C07D 215/58
A61K 45/06
A61K 31/5377
A61K 31/496
A61K 31/4704
C07D 491/147
A61K 31/4375

Abstract:

A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of:wherein X is N, C(OH), or CH;Y is H or OH;each of Z-Zis independently H or halogen;Ris H, OH, NH, NHR, NRRor R;R, R, and Ris each independently H, halogen, OR, R, NHR, NRR, COR, CONRR, SONRR, or Rand Rtogether with the carbon atoms to which Rand Rare attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; andRand Ris each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or Rand Rtogether with the nitrogen to which Rand Rare attached form an optionally-substituted heterocycle.

US Patent:

20160083382, Mar 24, 2016

Filed:

May 13, 2014

Appl. No.:

14/891309

Inventors:

- Bethesda MD, US
Steven Smith - Thurmont MD, US
Mathieu Metifiot - Saint Andre de Cubzac, FR
Barry Johnson - Chincoteague VA, US
Christophe Marchand - Silver Spring MD, US
Stephen H. Hughes - Smithsburg MD, US
Yves Pommier - Bethesda MD, US

Assignee:

The United States of American, as represented by the Sec, Dept. of Health and Human Services - Bethesda MD

International Classification:

C07D 471/04

Abstract:

A method of inhibiting drug-resistant HIV-1 integrase in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, having a structure of:wherein X is N, C(OH), or CH;Y is H or OH;each of Z-Zis independently H or halogen;Ris H, OH, NH, NHR, NRRor R;R, R, and Ris each independently H, halogen, OR, R, NHR, NRR, COR, CONRR, SONRR, or Rand Rtogether with the carbon atoms to which Rand Rare attached form an optionally-substituted carbocycle or optionally-substituted heterocycle; andRand Ris each independently H, optionally-substituted alkyl, optionally-substituted alkenyl, optionally-substituted alkynyl, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted cycloalkylene, optionally-substituted heterocycle, optionally-substituted amide, optionally-substituted ester, or Rand Rtogether with the nitrogen to which Rand Rare attached form an optionally-substituted heterocycle.

US Patent:

20140273137, Sep 18, 2014

Filed:

Mar 15, 2013

Appl. No.:

13/837654

Inventors:

The Unites Stated of America, as represented by the Secretary of Agriculture - , US
Dwayne R. Roach - Laurel MD, US
Piyum A. Khatibi - Dunlap IL, US
Kenneth M. Bischoff - Morton IL, US
Stephen R. Hughes - Peoria IL, US

Assignee:

The United States of America, as represented by the Secretary of Agriculture - Washington DC

International Classification:

C12P 7/10
C12P 7/06

US Classification:

435165, 435161, 435163

Abstract:

Ethanol losses due to bacterial contamination in fermentation cultures weakens the economics of biofuel production. species are the predominant contaminant. Bacteriophage lytic enzymes are peptidoglycan hydrolases which degrade Gram positive cell walls when exposed externally and are a novel source of antimicrobials. The streptococcal phage λSA2 endolysin construct demonstrated strong lytic activity towards 17 of 22 strains of lactobacilli, staphylococci or streptococci maintaining optimal specific activity under fermentation conditions toward substrates. bacteriophage endolysin constructs LysA, LysA2 and LysgaY showed exolytic activity towards 60% of the lactobacilli tested including four isolates from fuel ethanol fermentations. Presence of ethanol (≦5%) did not affect lytic activity. Lysins were able to reduce both and contaminants in mock fermentations of corn fiber hydrolysates. Recombinant LysA and λSa2 expressed in the yeast are functional; LysA was shown to reduce lactobacilli in experimentally infected fermentations.